Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

European regulators are to review Sandoz's biosimilars of the inflammatory diseases medicines, Humira and Remicade, as competition intensifies to take market share from big-selling monoclonal anti ...

It is going up against several mature product franchises, including Amgen's Enbrel (etanercept), Abbott's Humira and Remicade, marketed in the US by J&J and in Europe by Merck of Whitehouse ...